BENSALEM, Pa., May 16, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).Class Period: December 1, 2023 – April 26, 2024Lead Plaintiff Deadline: July 5, 2024Investors suffering losses on their Altimmune investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class actio ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and Ap ...

NEW YORK, May 15, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), of the important July 5, 2024 lead plaintiff deadline.SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.WHAT TO DO NE ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Rich Eisenstadt - Chief Financial Officer Vipin Garg - President & Chief Executive Officer Scott Harris - Chief Medical Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Roger Song - Jefferies Alana Lelo - Guggenheim Mayank Mamtani - B. Riley Securities Jon Wolleben - Citizens JMP Operator Good day, ladies and gentlemen and welcome to Altimmune Inc. First Quarter 2024 Financi ...

Exhibit 99.1 Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, MD – May 9, 2024 – Altimmune, Inc. (Nasdaq: ALT), a clinicalstage biopharmaceutical company, toda ...

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/inv ...

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA)    Title: Focusing on the Use of GLP ...

Altimmune团队对Stephen Harrison博士的悼念 - Altimmune团队对Stephen Harrison博士的意外离世表示悲痛和诚挚的哀悼[1] - Altimmune团队将怀念他，并感谢曾经与他相识和合作的机会[3] Harrison博士的贡献 - Harrison博士在代谢性肝病治疗方面的贡献将在我们领域留下深远而持久的影响[2]

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity spending is e ...